377 related articles for article (PubMed ID: 24904213)
1. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect.
Nehoff H; Parayath NN; Domanovitch L; Taurin S; Greish K
Int J Nanomedicine; 2014; 9():2539-55. PubMed ID: 24904213
[TBL] [Abstract][Full Text] [Related]
2. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
3. Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.
Dong X; Chu D; Wang Z
Theranostics; 2017; 7(3):751-763. PubMed ID: 28255364
[TBL] [Abstract][Full Text] [Related]
4. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
5. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications.
Durymanov M; Kamaletdinova T; Lehmann SE; Reineke J
J Control Release; 2017 Sep; 261():10-22. PubMed ID: 28625673
[TBL] [Abstract][Full Text] [Related]
6. The role of nanotechnology in gastrointestinal cancer.
Vyas D; Castro P; Saadeh Y; Vyas A
J Biomed Nanotechnol; 2014 Nov; 10(11):3204-18. PubMed ID: 26000381
[TBL] [Abstract][Full Text] [Related]
7. Nanobiotechnology and its applications in drug delivery system: a review.
Khan I; Khan M; Umar MN; Oh DH
IET Nanobiotechnol; 2015 Dec; 9(6):396-400. PubMed ID: 26647817
[TBL] [Abstract][Full Text] [Related]
8. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
[TBL] [Abstract][Full Text] [Related]
9. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.
Waite CL; Roth CM
Crit Rev Biomed Eng; 2012; 40(1):21-41. PubMed ID: 22428797
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting via EPR: Strategies to enhance patient responses.
Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
[TBL] [Abstract][Full Text] [Related]
11. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the enhanced permeability and retention effect for tumor targeting.
Iyer AK; Khaled G; Fang J; Maeda H
Drug Discov Today; 2006 Sep; 11(17-18):812-8. PubMed ID: 16935749
[TBL] [Abstract][Full Text] [Related]
13. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
14. Translational application of nano delivery systems: emerging cancer therapy.
Chougule MB; Tan C
AAPS PharmSciTech; 2015 Feb; 16(1):3-4. PubMed ID: 25549791
[No Abstract] [Full Text] [Related]
15. Size matters: gold nanoparticles in targeted cancer drug delivery.
Dreaden EC; Austin LA; Mackey MA; El-Sayed MA
Ther Deliv; 2012 Apr; 3(4):457-78. PubMed ID: 22834077
[TBL] [Abstract][Full Text] [Related]
16. Principles of nanoparticle design for overcoming biological barriers to drug delivery.
Blanco E; Shen H; Ferrari M
Nat Biotechnol; 2015 Sep; 33(9):941-51. PubMed ID: 26348965
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.
Lee MS; Dees EC; Wang AZ
Oncology (Williston Park); 2017 Mar; 31(3):198-208. PubMed ID: 28299757
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Brave new world - Focus on nanomedicine.
Alexiou C; Fadeel B
Biochem Biophys Res Commun; 2015 Dec; 468(3):409-10. PubMed ID: 26518649
[No Abstract] [Full Text] [Related]
19. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
20. Lipid-enveloped hybrid nanoparticles for drug delivery.
Tan S; Li X; Guo Y; Zhang Z
Nanoscale; 2013 Feb; 5(3):860-72. PubMed ID: 23292080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
